Sanofi to buy Belgian biopharmaceutical firm Ablynx for EUR3.9bn
Sanofi has offered €45 for each of the shares of Ablynx in an all-cash deal. The acquisition will help Sanofi advance the transformation of its research and development
Shanghai Henlius Biotech (Henlius) and Organon have announced the US Food and Drug Administration (FDA) acceptance of the biologic license application (BLA) for HLX14, a biosimilar candidate of PROLIA/XGEVA (denosumab).
The company has announced the top-line results from the Phase III KRONOS trial, which showed PT010 (budesonide/glycopyrronium/formoterol fumarate 320/14.4/9.6µg, using Aerosphere Delivery Technology, in a pressurised metered-dose inhaler
GEP-NET is a form of cancer that affects the pancreas or gastrointestinal tract. The approval is for adult patients with somatostatin receptor-positive GEP-NETs and it covers conditions like foregut, midgut,
This designation is for treating patients diagnosed with HER2-positive metastatic breast cancer (MBC) that has progressed during or after at least two HER2-targeting treatment regimens for locally advanced